NCT01966289View on ClinicalTrials.gov

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 14, 2014

Primary Completion Date

June 6, 2020

Study Completion Date

June 6, 2020

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

CY

CY is administered intravenously at 200 mg/m2

BIOLOGICAL

GVAX

GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells

DRUG

SGI-110

SGI-110 is administered subcutaneously at 60 mg/m2

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Astex Therapeutics, Ltd
All Listed Sponsors
collaborator

Astex Therapeutics, Ltd

UNKNOWN

collaborator

Susan Cohan Colon Cancer Foundation

UNKNOWN

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01966289 - SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) | Biotech Hunter | Biotech Hunter